covid-19 death Ventilators patient

AstraZeneca to trial Calquence to treat Covid-19 patients

Reading now: 747
www.pharmaceutical-technology.com

AstraZeneca is set to conduct a global clinical trial of Calquence (acalabrutinib) to treat cytokine storm that manifests in severely ill Covid-19 patients.

Calquence is designed to selectively attach to and block the activity of Bruton’s tyrosine kinase (BTK). BTK signalling is known to stimulate pathways involved in B-cell proliferation, trafficking, chemotaxis and adhesion.

The drug holds approvals to treat chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) in adults. Named CALAVI, the trial will compare the safety and efficacy of the drug plus best supportive care (BSC) to BSC alone in patients hospitalised due to Covid-19-related respiratory complications.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA